Rethinking Skin Preparation: Is Hypochlorous Acid (Clinisept+) a Safe Alternative Skin Preparation in Aesthetic Surgery?
Aesthetic Plastic Surgery · 2026-06 · 50 (11) · 4631-4636
DOI: 10.1007/s00266-026-05806-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Aesthetic Plastic Surgery, online erschienen am 20.04.2026. Verfasst von Ali Arnaout und 7 weiteren Autor:innen. Beteiligte Einrichtung: LASE Cosmetic, Newcastle, UK. Hauptthemen laut MEDLINE: Hypochlorous Acid, Plastic Surgery Procedures, Preoperative Care, Surgical Wound Infection. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Surgical site infections (SSIs) in aesthetic surgery, though rare (~1%), can compromise outcomes. Standard preoperative antiseptics such as chlorhexidine gluconate (CHG) and povidone-iodine are effective but may cause irritation or toxicity. Clinisept+ is a stabilised hypochlorous acid (HOCl) solution with broad antimicrobial activity and excellent tissue compatibility, yet evidence for its surgical use is limited. METHODS: A prospective, multicentre audit was conducted in four UK private aesthetic surgery clinics (January-August 2024). All patients received Clinisept+ as the sole preoperative skin preparation. Demographics, smoking status, procedure type, antibiotic prophylaxis, SSIs, wound complications, and skin reactions were recorded. SSIs were defined as infections requiring treatment. Associations with smoking and antibiotic use were analysed with Fisher's exact test. RESULTS: A total of 157 patients (median age 45 years; 78% female) underwent diverse aesthetic procedures. The SSI rate was 1.27% (2/157), both minor and resolving with oral antibiotics. All SSIs occurred in smokers without prophylactic antibiotics (p = 0.04 vs non-smokers). Wound-healing complications occurred in 5.1% (8/157), none infected. No skin sensitivity or allergic reactions were reported. CONCLUSIONS: Clinisept+ yielded SSI rates comparable to historical data for CHG and povidone-iodine, with excellent tolerability and no observed skin irritation. HOCl-based preparation may be advantageous in patients with sensitive skin or when operating near mucosal or delicate regions. These findings support its safe use in aesthetic surgery, though randomised controlled trials are warranted to confirm non-inferiority. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LASE Cosmetic, Newcastle, UK.
- Royal Victoria Infirmary, Newcastle, UK.
- Purity Bridge, Tunbridge Wells, UK.
- Berkshire Grove Hospital, Maidenhead, UK.
- Adnova Clinic, Fareham, UK.
- LASE Cosmetic, Jesmond, Newcastle, UK. info@lasecosmetic.com.
Zitieren
APA
Arnaout, A., Goodarzi, M. R., Nugent, N. F., Pacifico, M. D., Urso-Baiarda, F., Durrant, C. A. T., Heppell, S., & Ali-Khan, A. S. (2026). Rethinking Skin Preparation: Is Hypochlorous Acid (Clinisept+) a Safe Alternative Skin Preparation in Aesthetic Surgery?. Aesthetic Plastic Surgery, 50(11), 4631-4636. https://doi.org/10.1007/s00266-026-05806-2
Vancouver
Arnaout A, Goodarzi MR, Nugent NF, Pacifico MD, Urso-Baiarda F, Durrant CAT, et al. Rethinking Skin Preparation: Is Hypochlorous Acid (Clinisept+) a Safe Alternative Skin Preparation in Aesthetic Surgery?. Aesthetic Plastic Surgery. 2026;50(11):4631-4636. doi:10.1007/s00266-026-05806-2
BibTeX
@article{Arnaout2026,
author = {Arnaout, Ali and Goodarzi, Mohammad R and Nugent, Nora F and Pacifico, Marc D and Urso-Baiarda, Fulvio and Durrant, Charles A T and Heppell, Simon and Ali-Khan, Ahmed S},
title = {Rethinking Skin Preparation: Is Hypochlorous Acid (Clinisept+) a Safe Alternative Skin Preparation in Aesthetic Surgery?},
journal = {Aesthetic Plastic Surgery},
year = {2026},
volume = {50},
number = {11},
pages = {4631--4636},
doi = {10.1007/s00266-026-05806-2}
}
EUVIMED